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Original Article
Vascular endothelial growth factor-A mRNA gene
expression in clinical phases of multiple sclerosis
Hoiyda A Abdel Rasol1,2, Hanan Helmy3, Sherine El-Mously4, Margeret A Aziz5 and
Hossam El bahaie6
Abstract
Background: Vascular endothelial growth factor A stimulates angiogenesis, but is also pro-inflammatory and plays an
important role in the development of neurological disease. This study aimed to investigate whether vascular endothelial
growth factor A mRNA expression could be used as a marker for the prediction of susceptibility to multiple sclerosis and
relate vascular endothelial growth factor to the clinical phases of multiple sclerosis.
Methods: This was a cross-sectional study, consisting of a total of 60 subjects with multiple sclerosis and 20 healthy
controls. Subjects were subjected to history taking, neurological examination and peripheral blood sampling for vascular
endothelial growth factor A mRNA gene expression. Vascular endothelial growth factor A gene expression was mea-
sured by real-time polymerase chain reaction using the SYBR Green technique.
Results: Vascular endothelial growth factor A mRNA gene expression level was significantly lower in the multiple
sclerosis group than in the healthy control group (P< 0.001). Vascular endothelial growth factor A mRNA gene expres-
sion level was higher in relapsing remitting multiple sclerosis (RRMS) patients than in those in remission (P< 0.001) and in
relapsing remitting multiple sclerosis compared with secondary progressive multiple sclerosis (P< 0.001). There was no
correlation between vascular endothelial growth factor A gene expression levels and duration of disease, multiple
sclerosis progression index or expanded disability status scale.
Conclusions: A lower vascular endothelial growth factor A mRNA gene expression level was independently associated
with a higher risk of multiple sclerosis.
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Introduction
Multiple sclerosis (MS) is an autoimmune disease of the
central nervous system (CNS) that in most cases is
characterized by a relapsing-remitting (RR) disease
course. With time, the disease progresses, with failure
of repair mechanisms leading to gradual neurodegen-
eration and a continuous increase in disability.1 Very
little is known about the mechanisms underlying the
transition to progressive MS disease, and the diagnosis
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of a progressive disease course is made solely on clinical
grounds, since reliable supporting laboratory or neuro-
radiological tests are lacking. This can cause problems
clinically, when making treatment decisions.2 The exact
aetiology of MS is unknown, but it is thought to
depend on a complex interaction between genetic and
environmental factors. Vascular endothelial growth
factor (VEGF) is an angiogenic and pro-inﬂammatory
factor with neuroprotective eﬀects on neuronal and
glial cells.
Results from some studies have indicated a role for
vascular endothelial growth factor-A (VEGF-A) in
MS.3–7 Increased expression of VEGF-A has been
detected in CNS tissue and serum in animal models
and in patients with MS.6 In addition, endothelial cell
proliferation and increased blood vessel density have
been documented in acute MS lesions,8 and experimen-
tal autoimmune encephalomyelitis (EAE).9 EAE is an
animal model for MS. It can be induced by immuniza-
tion using antigens derived from myelin. These antigens
elicit an acute demyelinating process driven by T cells
and macrophages which can have a chronic relapsing
course quite similar to MS.10 In EAE, VEGF-A is
expressed by monocytes and activated T cells and is
associated with a Th1 T-cell phenotype and increased
severity of inﬂammation.11
Some histopathological features of the MS lesions
resemble hypoxic damage, perhaps because of meta-
bolic disturbances. They also display an increased
expression of hypoxia inducible factor 1 a (HIF1a), a
transcription factor for VEGF-A.12
The study by Holley et al.13 demonstrated an
increase in blood vessel density in MS lesions compared
with normal healthy controls (HCs) and increased pro-
liferation of endothelial cells within these blood vessels.
These ﬁndings suggest that angiogenesis occurs in MS.
The aim of the present study was to determine
VEGF-A mRNA expression proﬁles in the whole
blood of subjects with MS and relate them to diﬀerent
disease subtypes. We also investigated a possible role of
VEGF-A during transition from relapsing remitting
multiple sclerosis (RRMS) to secondary progressive
MS (SPMS). In addition, we sought to ascertain if
there was any correlation between VEGF mRNA
gene expression and brain magnetic resonance imaging
(MRI) ﬁndings, age, multiple sclerosis severity score
(MSSS), expanded disability status scale (EDSS) and
disease duration.
Materials and methods
Subjects
A total of 60 MS patients (16 male and 44 female) at the
Department of Neurology, Cairo University Teaching
Hospital, Egypt were enrolled in this cross-sectional
study in 2013. The HC subjects were blood donors
(10 males and 10 females).
The subjects with MS consisted of: 20 with SPMS,
22 with RRMS and 18 with primary progressive MS
(PPMS). Of the 22 subjects with RRMS, 8/22 (36.4%)
were in relapse, deﬁned according to Schumacker
et al.14 and 14/22 (63.6%) were in remission. For
RRMS, a relapse was deﬁned as an increase with 51
point on the EDSS, with a duration of at least one week
prior to sampling, where systemic infection had been
ruled out. Remission was deﬁned as a stable clinical
status for three months prior to sampling. SPMS was
deﬁned as an initial RR disease course, followed by
more than 12 months of continuous worsening of
neurological function (5 0.5 EDSS point) not
explained by relapse.2 All subjects with MS were receiv-
ing treatment according to the clinical judgement of the
assessing neurologist. Disease-modifying treatments
included solumedrol (methylpredinsilone) (Pﬁzer
Company, Belgium) – 36/60 subjects (60%), Endoxan
(cyclophosphamide) (EIMC Company, Korea) – 10/60
subjects (16.7%) and solumedrol and Endoxan – 14/60
subjects (23.3%).
Inclusion criteria of MS subjects comprised the fol-
lowing: (1) deﬁnite MS according to the International
Panel on Diagnosis of MS, McDonald’s criteria 2010,15
(2) all types of MS, (3) gender: both male and female
subjects were recruited. Patients with clinical evidence
of autoimmune disease, arthritis, or infections prior to
or complicating the attack, or with clinical evidence of
myocardial infarction were excluded from the study.
Subjects with MS underwent history taking, general
and full neurological examination and MRI. Brain and
cervical MRI was performed on a 1.5 Tesla Phillips
Intera scanner. Diagnostic criteria incorporated MRI
and evoked potential testing (visual, auditory and som-
atosensory). Parallel information was recorded on dis-
ease duration, type of MS, relapse status, disability
measured by the EDSS16 and medications. The MSSS
was calculated from EDSS and disease duration.17
The IgG-speciﬁc oligoclonal banding in serum, CSF
and IgG CSF index were routinely analysed in the
Chemical Pathology Department.
The study was approved by the local ethics commit-
tee of our Institute. Informed consent was obtained
from all study subjects after the nature of the study
was explained.
Specimen collection
Two millilitres of EDTA blood were collected for the
determination of VEGF-A mRNA gene expression
(RNA extraction followed by complementary (c)
DNA generation and stored at 20C).
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Methods
Real-time polymerase chain reaction
mRNA levels of VEGF were assessed by a quantitative
real-time polymerase chain reaction (RT-PCR) assay
using glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) as a housekeeping gene. Total RNA was
extracted from 1mL of fresh blood collected into
EDTA tubes from patients and HC using an RNeasy
mini kit (Qiagen, Germany). cDNA was synthesized by
reverse transcription (RT) with the ThermoscriptTM
RT kit (Invitrogen, Berlin, Germany), using random
hexamers as ampliﬁcation primers. In detail, 2.5g of
total RNA, 50 ng of random hexamers and 1mM
dNTPs were heated at 65C for 5min. The ﬁnal mix
(20L) was incubated for 10min at 25C for primer
extension, and cDNA synthesis was conducted at
55C for 50min. The reaction was terminated by heat-
ing at 85C for 5min.
The primer sequences for GAPDH and primer
sequences for VEGF were designed with online soft-
ware Primer3 (http://www-genome.wi.mit.edu/cgi-bin/
primer/primer3wwwcgi) and were purchased from
Qiagen (Australia). VEGF was determined using
SYBR Green chemistry. Diluted (1/20) cDNA (4L)
was added to a PCR mix containing 2.4L sterile
water, 10L 2SYBR mix (Qiagen, Clifton Hill,
Victoria, Australia) and 1.5L each of forward and
reverse primers to make up a ﬁnal volume of 20L.
Cycling conditions for ampliﬁcation were 95C for
10min, followed by 40 cycles of 95C for 15 s, 60C
for 30 s and a ﬁnal step of 95C for 15 s, 60C for 15 s
and 95C for 15 s in a StepOneTM thermal cycler
(Applied Biosystems). The calculations of relative
gene expression were done using the CT method.
Because the amount of product doubles in each cycle,
the relative gene expression was calculated using the
formula 2 -CT.18
Statistical analysis
Statistical analyses were performed using SPSS
(Statistical Package for Social Sciences), version 17.19
Data were subjected to the Kolmogorov-Smirnov test
to determine the distribution and method of analysis.
Normally distributed quantitative variables were pre-
sented as the mean (SD), and therefore the comparisons
age between groups were performed using the Student’s
t-test. The following data, i.e. disease duration, EDSS,
MSSS and VEGF-A mRNA gene expression level
showed skewed distributions and were expressed as
medians (ranges). VEGF-A mRNA gene expression
levels between groups were compared using the
Mann-Whitney test. Stratiﬁed analysis based on forms
of MS was performed by the Kruskal-Wallis H test.
Categorical variables are cited as percentages. A chi-
square test was used to compare gender. The eﬀect of
demographic and clinical variables (age, disease dur-
ation, MSSS and EDSS) on VEGF-A mRNA gene
expression was determined individually with the
Spearman Rank correlation coeﬃcient (r). A P value
(two-tailed) <0.05 was considered statistically
signiﬁcant.
Results
The demographic characteristics, laboratory and MRI
ﬁndings and clinical features are summarized in
Table 1.
The gender and mean (SD) age did not diﬀer signiﬁ-
cantly between patients with MS and HC (P> 0.05).
There was a statistically signiﬁcant diﬀerence in
median mRNA VEGF expression level between the
HC 2.27 (range: 1.53–3.43) compared to subjects with
MS 1.11 (range: 0.01–11.30) (P< 0.001). There was a
statistically signiﬁcant diﬀerence in median mRNA
VEGF expression between HC and subjects in each of
the MS clinical types, RRMS, SPMS and PPMS
(P< 0.001). Similarly, median mRNA VEGF expres-
sion in subjects with RRMS in relapse was signiﬁcantly
diﬀerent to the median expression observed in subjects
with RRMS in remission and to that observed in HC
(P< 0.001), with the highest value found among those
subjects with RRMS in relapse.
The number of brain MRI lesions did not appear to
inﬂuence the median mRNA VEGF expression. The
median level in subjects with MS and who had5 9
MRI brain lesions was 1.23 (range: 0.05–11.30),
which did not diﬀer signiﬁcantly from the median
value seen in subjects with MS who had <9 MRI
brain lesions 0.98 (range: 0.01–10.90) (P> 0.05) (data
not shown). mRNA VEGF expression showed a posi-
tively correlation with age (r¼ 0.305, P< 0.05) and dis-
ease duration (r¼ 0.306, P< 0.05). There was no
correlation between mRNA VEGF expression and
other measures of disease severity: EDSS (r¼ 0.139,
P> 0.05) and MSSS (r¼ 0080, P> 0.05) (Table 2).
Discussion
The exact role of VEGF-A in cerebral injury and
inﬂammation is still unclear. There is substantial evi-
dence that VEGF-A is a pro-inﬂammatory factor and
can cause CNS damage. Inhibition of endogenous
VEGF-A can lead to decreased brain lesion size,
whereas administration of VEGF-A can exacerbate
CNS damage and up-regulate immunomodulatory
adhesion molecules and cytokines.20
The aim of this study was to quantify the expression
of VEGF-A mRNA from patients with MS in Egypt.
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The median value of VEGF mRNA expression in the
HC was signiﬁcantly diﬀerent to the median value
observed in subjects with MS, and also to the median
value in those subjects stratiﬁed by MS clinical type,
RRMS, SPMS and PPMS. There was also a statistic-
ally signiﬁcant diﬀerence in median mRNA VEGF
expression between subjects with RRMS in relapse
compared with those in remission and also with HC,
with the highest level of expression found among those
subjects with RRMS in relapse. The number of brain
MRI lesions did not inﬂuence median mRNA VEGF
expression. mRNA VEGF expression showed a posi-
tive correlation with age and also with disease duration.
Table 1. Demographic characteristics, laboratory and MRI findings and clinical features, of subjects with MS compared with healthy
controls.
MS subjects HC Significance
Number 60 20
Demographic characteristics
Age (years) mean (SD) 32.37 (6.58) 30.65 (4.39) P> 0.05
Gender
Male (n) (%)
Female (n) (%)
16/60 (26.7%)
44/60 (73.3%)
10/20 (50%)
10/20 (50%)
Odds ratio 0.364
95% CI
(0.128–1.036)
P> 0.05
Clinical features
EDSS score 2.5 (0.7–6)
MSSS score 1.22 (0.50–5.7)
Disease duration (years)
Median (minimum–maximum)
2 (0.7–5)
Brain MRI:
RRMS
(n¼ 22)
PPMS
(n¼ 18)
SPMS
(n¼ 20)
Nine or more
periventricular lesions
10/22 (45.4%) 10/18 (55.5%) 2/20 (10%)
Infratentorial lesion 10/22 (45.4%) 6/18 (33.3%) 14/20 (70%)
Juxtacortical lesion 12/22 (54.5%) 10/18(55.5%) 16/20 (80%)
VEGF-A mRNA gene expression, median (minimum–maximum)
MS cases and HC 1.11 (0.01–11.30) 2.27 (1.53–3.42) P< 0.001
MS subtypes and HC RRMS
(n¼ 22)
PPMS
(n¼ 18)
SPMS
(n¼ 20)
HC P< 0.001
2
(1.07–11.30)
2
(0.19–3.73)
0.25
(0.01–0.90)
2.27
(1.53–3.42)
RRMS in remission,
relapse and HC
RRMS-relapse
(n¼ 8)
RRMS-remission
(n¼ 14)
HC
(20)
P< 0.001 a
P< 0.001 b
6.88
(5.70–11.30)
1.57
(1.07–2.70)
2.27
(1.53–3.42)
MRI: magnetic resonance imaging; EDSS: Expanded Disability Status Scale; MSSS: Multiple Sclerosis Severity Score; MS: multiple sclerosis; VEGF-
A: vascular endothelial growth factor-A. Data are the number of subjects (percentage of the total group), chi square: values are the odds ratio (OR) and
95% confidence interval (95% CI), RR: relapsing-remitting; PP: primary progressive; SP: secondary progressive.
aP< 0.001¼RRMS in relapse compared with control.
bP< 0.001¼RRMS in relapse compared with RRMS in remission.
Table 2. Correlation between VEGF-A mRNA gene expression
level among subjects with MS and age, disease duration, EDSS and
MSSS.
r Significance
Age (years) 0.305 P< 0.05
Disease duration (years) 0.306 P< 0.05
EDSS score 0.139 P> 0.05
MSSS score 0.080 P> 0.05
EDSS: Expanded Disability Status Scale; MSSS: Multiple Sclerosis Severity
Score; r: correlation coefficient; MS: multiple sclerosis.
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There was no correlation between mRNA VEGF
expression and other measures of disease severity:
EDSS and MSSS. VEGF mRNA gene expression can
distinguish RRMS from SPMS.
The results of the present study showed a down-reg-
ulation of mRNA VEGF gene expression in whole
blood of subjects with MS compared with HC.
Results from studies performed on VEGF gene
expression, protein level and CSF level have been con-
troversial. Iacobaeus et al.2 demonstrated that the
expression of VEGF-A is down-regulated in CSF cells
irrespective of disease course, but that only patients
with SPMS display a down-regulation of VEGF-A
expression in peripheral blood mononuclear cells
(PBMCs) as compared to both subjects with RRMS
and to HC. These authors also measured VEGF-A pro-
tein levels, using an ELISA technique, in a small subset
of patients and demonstrated a non-signiﬁcant trend
towards decreased levels in those patients with SPMS
compared to both those with RRMS and also to HC.2
Seabrook et al.21 also, using ELISA, found a decreased
level of VEGF in subjects with MS. The expression of
VEGF during EAE is controversial, with both
increased as reported by Roscoe et al.22 and
Proescholdt et al.4 and decreased expression as reported
by Tham et al.3
Data from the study by Proeschold et al.4 have
shown that chronic administration of VEGF to
normal brain causes blood–brain barrier (BBB) break-
down of small and large molecules in vivo. Impairment
of BBB integrity is an early and consistent diagnostic
ﬁnding in MS, and could be an important aspect of the
pathogenesis of the disease. Chronic over-expression of
VEGF in reactive/gliotic astrocytes could contribute to
the permanent BBB breakdown within an MS plaque.23
In addition to the induction of increased microvascular
permeability, the studies by Ferrara,24 Melder et al.25
and Proescholdt et al.26 reported the up-regulation of
adhesion molecules on capillary endothelial cells by
VEGF in vivo. The expression of adhesion molecules
plays an important role in the process of lymphocyte
traﬃcking and homing during CNS inﬂammation.
The present study found that there was a signiﬁcant
diﬀerence in VEGF mRNA expression in whole blood
among MS subtypes compared with HC. Meanwhile, a
study by Iacobaeus et al.,2 performed using PBMC,
stated that patients with SPMS are characterized by a
prominent decrease of VEGF-A mRNA expression in
PBMC compared with both subjects with RRMS and
with HC, who display comparable levels of VEGF-A
expression. These authors suggested that down-regula-
tion of VEGF-A mRNA expression in PBMC reﬂects
an underlying disease mechanism that operates specif-
ically in patients with progressive MS, which was of
interest in the context of emerging evidence that
connects dysregulation of VEGF-A with neurodegen-
erative processes.2
In this study, we observed a signiﬁcant diﬀerence in
VEGF mRNA expression level in the whole blood of
patients with RRMS and who were in remission, com-
pared with those with RRMS and who were in relapse.
The study by Iacobaeus et al.2 using PBMC, found
no signiﬁcant diﬀerence in expression, between patients
with RRMS, whether in relapse or in remission. In add-
ition, there was a trend towards higher levels of VEGF-
A expression in PBMC from RRMS sampled during a
relapse as compared with patients in remission. The
study by Su et al.6 suggested that an increase in
serum VEGF concentration might be involved in MS
relapse.
These authors6 found that serum VEGF concentra-
tions were signiﬁcantly elevated in patients with MS in
relapse compared with both HC and those in remis-
sion, irrespective of clinical subtype. An increase of
VEGF-A concentration in the initial phases of relapse
is compatible with its role as a pro-inﬂammatory
factor that attracts monocytes and lymphocytes, up-
regulates immunomodulatory adhesion molecules,
stimulates secretion of pro-inﬂammatory cytokines
and increases BBB permeability.3,20 Stockhammer
et al.27 measured serum VEGF in 19 patients with
MS and with unspeciﬁed clinical phases and found
no elevation of VEGF. Proescholdt et al.4 reported
the up-regulation of VEGF in MS lesions as well as
in acute lesions in rats with EAE, an animal model of
MS. Croll et al.20 demonstrated decreased levels of
VEGF-A protein in rat spinal cord tissue during
EAE relapse and a reduced expression in neurons fol-
lowing immunohistochemistry. Iocobaeus et al.2 found
no signiﬁcant diﬀerence between relapse and remission
in CSF. Seabrook et al.21 demonstrated that neuronal
expression of VEGF was present during acute EAE,
whereas during the relapse phase, neuronal VEGF
decreased.
Manoonkitiwongsa et al.28 stated that the discrep-
ancy in their results could be related to the timing of
sampling in relation to the onset of relapse symptoms
or the occurrence of subclinical disease activity in the
remission group. It is known that the net eﬀect of
VEGF-A can vary depending on the target tissue, the
timing and the concentration.
VEGF has been shown to be associated with age-
associated diseases, such as neovascular age-related
macular degeneration.29,30 In the present study, there
was a correlation between VEGF and age and disease
duration, in agreement with the ﬁndings reported by
Mould et al.31 However, there was no correlation
between VEGF mRNA expression and EDSS and
MSSI, a ﬁnding consistent with those of others.2,6
The lack of correlation between VEGF and EDSS
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scores could be explained by the fact that the latter
are determined by dysfunction in various parts of
the CNS.
Although angiogenesis is probably not the ﬁrst event
in the pathogenesis of MS, its changing role in the dif-
ferent phases of disease progression makes it an import-
ant and underestimated target in therapeutic options.
The current concept of the natural history of MS refers
to a combination of two phenomena underlying the two
phases of MS, namely an inﬂammatory process in the
remitting phase and a neurodegenerative process in the
progressive phase. The secondary progressive phase of
MS is primarily caused by axonal degeneration follow-
ing demyelination. The potential advantages of inhibit-
ing angiogenesis in the early phase of MS could stem
from reducing the vascular supply of nutrients and
inﬂammatory cells to the demyelinating lesions, halting
the production of endothelial-derived pro-inﬂamma-
tory molecules. This approach should be proposed
only in aggressive acute relapsing MS, where immuno-
suppression could be associated with speciﬁc antiangio-
genic therapy. Considering the central role of VEGF
signalling in pathological angiogenesis during the
early MS phase, anti-VEGF therapy should be highly
beneﬁcial in the aggressive MS-subtype. 10
In conclusion, we have demonstrated that expression
of VEGF-A is down-regulated in subjects with MS
compared with HC. Thus, VEGF-A mRNA expression
may reﬂect an underlying disease mechanism that oper-
ates speciﬁcally in progressive MS. In contrast, there
was a signiﬁcant increase in expression in those subjects
with RRMS and who were in relapse, compared with
expression in HC and in those patients with RRMS
who were in remission. mRNA VEGF gene expression
level did not correlate with any of the parameters of
disease severity.
Since genotypes encoding higher VEGF production
are reportedly associated with diabetic microvasculopa-
thy32 and acute renal allograft rejection,33 and since
signiﬁcant ethnic diﬀerences in polymorphisms of the
VEGF gene have also been reported,34 we believe such
polymorphisms warrant future investigation in patients
with MS, especially those of African origin. Further
studies in larger clinical settings are needed to address
the question of whether dysregulated VEGF-A expres-
sion in MS is a cause or a consequence of a progressive
disease phenotype.
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